Deutsche Bank reiterates Buy on Gilead Sciences stock, $155 target By Investing.com

Gilead agreed to acquire Ouro Medicines for up to $2.18B ($1.675B upfront + up to $500M milestones). Weekly Yeztugo prescriptions reached ~786 for the week ending Mar 20, 2026 (+3% week-over-week) with a trailing four-week growth of ~2%; Deutsche Bank models Q1 2026 sales of ~$118M without adjustments and ~$168M with a 70% capture adjustment (consensus $144M, DB prior $123M). Deutsche Bank reiterated Buy with a $155 target and analyst reactions range from Bernstein Outperform $160 and Truist Buy $152 to Goldman Sachs Neutral $125, signaling generally positive but varied market views.

Analysis

The immediate market signal is that Gilead’s launch trajectory is far more model-sensitive than headline growth implies: small downward adjustments to historical prescription datasets or modest changes in payer capture assumptions can create double-digit swings in quarterly revenue versus consensus. That sensitivity amplifies volatility around scheduled data revisions and payer formulary re-negotiations, making near-term prints binary for the stock and for analysts’ models.

Secondary effects matter: data-provider revisions reduce the informational advantage of early-prescription reads, compressing alpha for fundamental short-term traders and increasing the value of event-driven and options strategies. Separately, strategic M&A that repositions pipeline focus away from established franchises can both de-risk long-term growth and dilute near-term ROIC expectations — investors priced for stable margin conversion will re-rate when strategic cash is redeployed into adjacent immunology areas.

Competitor dynamics are nuanced: long-acting injectable PrEP and entrenched HIV care pathways create a ceiling on oral PrEP penetration regardless of marketing push, so sustainable market share gains require durable refill behavior and favorable PBM contracts. That makes payer carry and capture the dominant variable for returns; if payers extract material price concessions in exchange for placement, volume upside must be large and sticky to offset margin erosion, a high bar over the next 6–12 months.

Key Decisions for Investors

• Long GILD equity (6–12 months) + buy 9–12 month protective put (e.g., ~10–15% OTM) — asymmetric upside if capture/clinical optionality re-accelerates post-acquisition while put caps headline risk from data-revision or payer setbacks; target 20–30% upside vs 8–12% downside-plus-premium.
• Event trade: ahead of the next scheduled historical data revision, buy a defined-cost upside (call spread) on GILD with expiration 1–3 months out to play a possible upside surprise from stronger-than-implied capture; cap max loss to premium, target 2–3x payoff if adoption momentum re-accelerates.
• Relative-value: long GILD / short IQV (3–6 months) — IQV downside priced-in if market focuses on data-quality headlines while Gilead’s fundamentals and M&A optionality remain intact; hedge size to limit index and sector beta, aim for 1:1 dollar exposure and a 15–25% relative outperformance objective.
• Risk-off hedge: accumulate short-dated puts on GILD or buy inverse biotech exposure for tactical protection around earnings and payer-negotiation windows (days–weeks) — expect higher implied vol and pay a finite premium to avoid overnight gap risk tied to revision announcements.